Skip to main contentSkip to navigationSkip to search

Additional US patent application relating to uTRACE[®] is accepted for grant

April 22, 2022


The United States Patent and Trademark Office has announced that Curasight’s United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137. The patent strengthens Curasights IP protection and supports the US commercial strategy. 

Curasight (the Company) is a pioneer in the field of exploiting the Positron Emissions Tomography (PET) imaging platform targeting the receptor uPAR, which is a known biomarker of cancer aggressiveness, to be used for improved diagnosis in multiple types of cancer. This patent application relates to Curasight’s diagnostic technology uTRACE® (imaging agent 64Cu-DOTA-AE105) and uses thereof until 2040.

Curasight has developed a novel radiopharmaceutical platform uTRACE® for improved diagnose, risk stratification and treatment monitoring for cancer patients based on uPAR PET imaging within different cancer indications.  Together with uTREAT®, the combination is known as uPAR Theranostics – the combination of therapy and diagnostics.

For Curasight the addition of this granted US patent - based on the 64Cu-imaging agent is an important milestone in the development of uTRACE® as a comprehensive diagnostic platform for uses in many cancer indications. Together with the already issued patent for uTRACE® based on the 68Ga imaging agent, the uTRACE® platform now consist of two imaging agents both targeting uPAR but with different characteristics. The addition of a second compound is of great importance for our commercial strategy and means that we will have a strong position in the North American market - especially for healthcare providers who prefer to use Cu (copper) as the radioactive isotopes,” says CEO Ulrich Krasilnikoff.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.